Phaseline

Companies › iTeos Therapeutics

iTeos Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 1; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Inupadenant (EOS100850)
Adenosine 2A receptor antagonist
ADORA2APhase 2Metastatic NSCLC - Non-Small Cell Lung Cancer–
EOS301984
IKAROS degrader
–Phase 1Advanced Solid Tumors–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05403385Inupadenant (EOS100850)Phase 2Metastatic NSCLC - Non-Small Cell Lung CancerOncologyJun 2025
NCT06547957EOS301984Phase 1Advanced Solid TumorsOncologyDec 2025

Targets

ADORA2A (1)

Companies with the same targets

Arcus Biosciences TJ Biopharma Gilead Sciences RDC Clinical Zhejiang Vimgreen Pharmaceuticals GE Healthcare Innolake Biopharm AstraZeneca

Companies built like this

Can-Fite BioPharma Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) TJ Biopharma ALX Oncology Shanghai EpimAb Biotherapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.